Recommendations for Addressing Suicidal Ideation Precipitated by Levetiracetam in the Treatment of Seizure Disorder: A Case Report and Review of the Literature
- PMID: 40809619
- PMCID: PMC12349744
- DOI: 10.7759/cureus.87919
Recommendations for Addressing Suicidal Ideation Precipitated by Levetiracetam in the Treatment of Seizure Disorder: A Case Report and Review of the Literature
Abstract
Suicidal ideation with levetiracetam is a relatively common occurrence in psychiatry and neurology practices. However, there are no established treatment guidelines, and more empirical evidence is needed to guide medical management in these cases. This report describes the case of a 17-year-old male patient with a history of poorly controlled epilepsy on oxcarbazepine who developed worsening anxiety after the initiation of levetiracetam and presented with suicidal ideation for the past three weeks; this was effectively managed with comprehensive care in our inpatient psychiatric center, resulting in the resolution of these thoughts. To support this case, we conducted a literature review using MEDLINE (Medical Literature Analysis and Retrieval System Online), PubMed, and Google Scholar to explore existing treatment protocols for patients experiencing suicidal ideation related to levetiracetam. This study proposes a treatment protocol, presented as a flowchart, that outlines various treatment modalities based on assessed risk factors in patients with suicidality associated with levetiracetam. We conclude that establishing a psychiatric treatment protocol will enable providers to effectively manage an amenable risk factor of suicidality. There is a need for further evidence-based research studies to strengthen our proposed treatment protocol.
Keywords: anti epileptics; levetiracetam; psychiatric disorders; recommendation; self-harm; suicidal ideation.
Copyright © 2025, Zamani et al.
Conflict of interest statement
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Ann Manzardo declare(s) a grant and PWSA(USA) 2023 Medical & Scientific Conference from Health Resources and Services (HRSA) Grant, LivaNova. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures

Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Prevention of self-harm and suicide in young people up to the age of 25 in education settings.Cochrane Database Syst Rev. 2024 Dec 20;12(12):CD013844. doi: 10.1002/14651858.CD013844.pub2. Cochrane Database Syst Rev. 2024. PMID: 39704320
-
Why Are Autistic People More Likely to Experience Suicidal Thoughts? Applying the Integrated Motivational-Volitional Model with Autistic Adults.Autism Adulthood. 2024 Sep 16;6(3):272-283. doi: 10.1089/aut.2023.0039. eCollection 2024 Sep. Autism Adulthood. 2024. PMID: 39371353
-
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.Cochrane Database Syst Rev. 2022 Apr 1;4(4):CD011412. doi: 10.1002/14651858.CD011412.pub4. Cochrane Database Syst Rev. 2022. PMID: 35363878 Free PMC article.
-
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD001901. doi: 10.1002/14651858.CD001901.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972056 Free PMC article.
References
-
- Preventing Suicide: A Global Imperative. Geneva, Switzerland: World Health Organization; 2014. World Health Organization. Preventing suicide: A global imperative.
-
- Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Kim JE, Choi HC, Song HK, et al. Neurosci Lett. 2010;471:94–99. - PubMed
-
- Psychiatric adverse events during levetiracetam therapy. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Neurology. 2003;61:704–706. - PubMed
-
- Levetiracetam and suicidality: a case report and literature review. Esang M, Santos MG, Ahmed S. https://www.psychiatrist.com/pcc/levetiracetam-and-suicidality/ Prim Care Companion CNS Disord. 2020;22 - PubMed
-
- Levetiracetam: a comprehensive review. Crepeau AZ, Treiman DM. Expert Rev Neurother. 2010;10:159–171. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous